"But doctors do it...": Nurses' views of gifts and information from the pharmaceutical industry

Annals of Pharmacotherapy

Volumn 43, Issue 6, 2009, Pages 1057-1063

  Jutel, Annemarie ^b   Menkes, David B ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b OTAGO POLYTECHNIC   (New Zealand)

Author keywords

Nursing; Pharmaceutical marketing

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG MARKETING; FEMALE; FUNDING; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MEDICAL ETHICS; NURSE; NURSING PRACTICE; NURSING PROTOCOL; PRESCRIPTION; PRIORITY JOURNAL;

ATTITUDE OF HEALTH PERSONNEL; CONGRESSES AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; FEMALE; GIFT GIVING; HUMANS; MALE; MARKETING; NEW ZEALAND; NURSES;

EID: 67249140122     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M027     Document Type: Article

References (42)

1. Moynihan R, Doran E, Henry D. Disease mongering is now part of the global health debate. PLoS Med 2008;5:e106. (Pubitemid 351760891)
2. Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med 2006;3:e191.
3. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003;169:405-412 (Pubitemid 37076252)
4. Mahon S. Impact of direct-to-consumer advertising on healthcare providers and consumers. Clin J Oncol Nurs 2006;10:417-420
5. Mansfield PR, Mintzes B, Richards D, Toop L. Direct to consumer advertising. BMJ 2005;330:5-6. (Pubitemid 40070466)
6. Mansfield PR, Mintzes B. Direct-to-consumer advertising is more profitable if it is misleading. N Z Med J 2003;116:U610. (Pubitemid 41386954)
7. Mintzes B, Barer ML, Kravitz RL, et al. Influence of direct-to-consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002;324:278-279 (Pubitemid 34121841)
8. Healy D. The latest mania: selling bipolar disorder. PLoS Med 2006;3:e185.
9. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-380
10. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA 2001;285:2009-2012 (Pubitemid 32366957)
11. Smith R. Medical journals and pharmaceutical companies: uneasy bed-fellows. BMJ 2003;326:1202-1205
12. Smith R. Making progress with competing interests - still some way to go (editorial). BMJ 2002;325:1375-1376
13. Baker C, Johnsrud MT, Crismon M, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003;183:498-506. (Pubitemid 37533195)
14. Boyd EA, Bero LA. Assessing faculty financial relationships with industry: a case study. JAMA 2000;284:2209-2214
15. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-1176 (Pubitemid 36649048)
16. Moncrieff J, Hopker S, Thomas P. Psychiatry and the pharmaceutical industry: who pays the piper? Psychiatr Bull R Coll Psychiatr 2005;29:84-85
17. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162:1957-1960 (Pubitemid 41428627)
18. Wager E. How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. BMJ 2003;326:1196-1198 (Pubitemid 36649058)
19. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Cha A-W. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007;4:e19. (Pubitemid 46191820)
20. Stanford University. Policy and guidelines for interactions between the Stanford University School of Medicine, the Stanford Hospital and Clinics, and Lucile Packard Children's Hospital with the pharmaceutical, biotech, medical device, and hospital and research equipment and supplies industries ("Industry"). 2006. http://med.stanford.edu/coi/siip/documents/siip- policy-aug06.pdf (accessed 2009 Feb 12).
21. Geppert CM. Medical education and the pharmaceutical industry: a review of ethical guidelines and their implications for psychiatric training. Acad Psychiatry 2007;31:32-39
22. Smith R. Conflicts of interest: how money clouds objectivity. J R Soc Med 2006;99:292-297 (Pubitemid 44013741)
23. Ashmore R, Carver N, Banks D. Mental health nursing students' relationships with the pharmaceutical industry. Nurse Educ Today 2007;27:551-560
24. Civaner M, Sarikaya O, Alici SU, Bozkurt G. Exposing nursing students to the marketing methods of pharmaceutical companies. Nurs Ethics 2008;15:396-410.
25. Monaghan MS, Galt KA, Turner PD, et al. Student understanding of the relationship between the health professions and the pharmaceutical industry. Teach Learn Med 2003;15:14-20. (Pubitemid 37026183)
26. Viale PH. Direct-to-consumer advertising of prescription medications: implications for patients with cancer. Oncol Nurs Forum 2002;29:505-513
27. Nolan P, Carr N, Doran M. Nurse prescribing: the experiences of psychiatric nurses in the United States. Nurs Stand 2004;18:33-38
28. Arnold M. The hidden prescribers. Med Mark Media 2004;39:44-52.
29. Researched Medicines Industry Association of New Zealand Incorporated. Code of Practice. Wellington, NZ: 2006.
30. Rogelberg SG, Stanton JM. Introduction: understanding and dealing with organizational survey nonresponse. Organ Res Meth 2007;10:195-209.
31. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med 2005;20:777-786 (Pubitemid 41141015)
32. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med 2000;15:478-483 (Pubitemid 30640259)
33. Sagarin BJ, Cialdini RB, Rice WE, Serna SB. Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion. J Pers Soc Psychol 2002;83:526-541
34. Watkins RS, Kimberly J Jr. What residents don't know about physician-pharmaceutical industry interactions. Acad Med 2004;79:432-437 (Pubitemid 38544297)
35. Mansfield PR. Is it insulting to suggest that health professionals are influenced by drug companies? Healthy Skepticism International News 2007;25:5.
36. Jutel A, Menkes DB. Soft targets: nursing and the pharmaceutical industry. PLoS Med 2008;5:e5. (Pubitemid 351317649)
37. deSilets L. Commercial support for professional development. J Contin Educ Nurs 2006;37:52-53
38. Jones M. Case report. Nurse prescribing: a case study in policy influence. J Nurs Manag 2004;12:266-272 (Pubitemid 38969599)
39. Goodell T. Evidence, please. PLoS Med Responses 2008. www.plosmedicine.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10. 1371%2Fannotation%2Fc76e997b-c220-493b-a535-914e3f1202dd&root= info%3Adoi%2F10.1371%2Fannotation%2Fc76e997b-c220-493b-a535-914e3f1202dd
40. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine house staff toward pharmaceutical industry promotions. Am J Med 2001;110:551-557
41. Braithwaite D, Emery J, de Lusignana S, Sutton S. Using the Internet to conduct surveys of health professionals: a valid alternative? Fam Pract 2003;20:545-551
42. Gore-Felton C, Koopman C, Bridges E, Thoresen C, Spiegel D. An example of maximizing survey return rates: methodological issues for health professionals. Eval Health Prof 2002;25:152-168 (Pubitemid 34507357)